Corina Dota

588 total citations
20 papers, 389 citations indexed

About

Corina Dota is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Corina Dota has authored 20 papers receiving a total of 389 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Cardiology and Cardiovascular Medicine, 12 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Corina Dota's work include Cardiac electrophysiology and arrhythmias (13 papers), Receptor Mechanisms and Signaling (6 papers) and ECG Monitoring and Analysis (5 papers). Corina Dota is often cited by papers focused on Cardiac electrophysiology and arrhythmias (13 papers), Receptor Mechanisms and Signaling (6 papers) and ECG Monitoring and Analysis (5 papers). Corina Dota collaborates with scholars based in Sweden, United Kingdom and United States. Corina Dota's co-authors include Christine Garnett, Georg Ferber, James J. Keirns, Börje Darpö, Norman Stockbridge, Nenad Sarapa, Kevin Krudys, Steve Riley, Charles Benson and Catherine Ortemann‐Renon and has published in prestigious journals such as Cancer Research, Clinical Pharmacology & Therapeutics and Toxicological Sciences.

In The Last Decade

Corina Dota

19 papers receiving 365 citations

Peers

Corina Dota
Lucette Doessegger Switzerland
Michael W. Bolt United States
Carmen M. Dumaual United States
Ashit Trivedi United States
Acton Rt United States
Russell Wada United States
E. Worth United Kingdom
Lucette Doessegger Switzerland
Corina Dota
Citations per year, relative to Corina Dota Corina Dota (= 1×) peers Lucette Doessegger

Countries citing papers authored by Corina Dota

Since Specialization
Citations

This map shows the geographic impact of Corina Dota's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Corina Dota with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Corina Dota more than expected).

Fields of papers citing papers by Corina Dota

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Corina Dota. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Corina Dota. The network helps show where Corina Dota may publish in the future.

Co-authorship network of co-authors of Corina Dota

This figure shows the co-authorship network connecting the top 25 collaborators of Corina Dota. A scholar is included among the top collaborators of Corina Dota based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Corina Dota. Corina Dota is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Parkinson, Joanna, Dinko Rekić, Karin Nelander, et al.. (2024). The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses. Pharmacology Research & Perspectives. 12(2). e1184–e1184. 2 indexed citations
3.
Parkinson, Joanna, Corina Dota, Magnus Bjursell, et al.. (2022). Verinurad does not prolong QTc interval: a thorough QT study using concentration–QTc modelling. British Journal of Clinical Pharmacology. 89(6). 1747–1755. 2 indexed citations
4.
Rekić, Dinko, Victor Sokolov, Catarina Nilsson, et al.. (2022). AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval. British Journal of Clinical Pharmacology. 88(11). 4839–4844. 11 indexed citations
5.
Voronova, Veronika, Marie Cullberg, Joanna Parkinson, et al.. (2021). Concentration‐QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations. British Journal of Clinical Pharmacology. 88(2). 858–864. 6 indexed citations
6.
Berges, Aliénor, et al.. (2021). QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small‐Molecule New Drug Applications Approved During 2011‐2019. The Journal of Clinical Pharmacology. 61(8). 1106–1117. 12 indexed citations
7.
Dota, Corina, Weili Yan, Remy B. Verheijen, et al.. (2021). A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, Three‐Way Crossover Study in Healthy Participants to Investigate the Effect of Savolitinib on the QTc Interval. Clinical Pharmacology in Drug Development. 10(5). 521–534. 5 indexed citations
8.
Berges, Aliénor, Corina Dota, Helen Tomkinson, et al.. (2021). Concentration‐QT modelling in early clinical oncology settings: Simulation evaluation of performance. British Journal of Clinical Pharmacology. 88(3). 1010–1019. 5 indexed citations
9.
Någård, Mats, Mei-Lin Ah-See, Karen So, et al.. (2020). Abstract 591: Adavosertib (AZD1775) does not prolong QT interval in patients with advanced solid tumors: A Phase I open-label study. Cancer Research. 80(16_Supplement). 591–591. 1 indexed citations
10.
Darpö, Börje, Charles Benson, Corina Dota, et al.. (2019). Evaluation of the Effect of 5 QT‐Positive Drugs on the JTpeak Interval — An Analysis of ECGs From the IQ‐CSRC Study. The Journal of Clinical Pharmacology. 60(1). 125–139. 3 indexed citations
11.
Cheung, S. Y. Amy, Joanna Parkinson, Corina Dota, et al.. (2018). A tutorial on model informed approaches to cardiovascular safety with focus on cardiac repolarisation. Journal of Pharmacokinetics and Pharmacodynamics. 45(3). 365–381. 5 indexed citations
12.
Pollard, Christopher E., Matthew Skinner, Stanley E. Lazic, et al.. (2017). An Analysis of the Relationship Between Preclinical and Clinical QT Interval-Related Data. Toxicological Sciences. 159(1). 94–101. 42 indexed citations
13.
Swaisland, Helen, Ruth Plummer, Karen So, et al.. (2016). Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies. Cancer Chemotherapy and Pharmacology. 78(4). 775–784. 12 indexed citations
14.
Ferber, Georg, Meijian Zhou, Corina Dota, et al.. (2016). Can Bias Evaluation Provide Protection Against False‐Negative Results in QT Studies Without a Positive Control Using Exposure‐Response Analysis?. The Journal of Clinical Pharmacology. 57(1). 85–95. 21 indexed citations
15.
Darpö, Börje, Charles Benson, Corina Dota, et al.. (2015). Results From the IQ‐CSRC Prospective Study Support Replacement of the Thorough QT Study by QT Assessment in the Early Clinical Phase. Clinical Pharmacology & Therapeutics. 97(4). 326–335. 141 indexed citations
16.
Darpö, Börje, Nenad Sarapa, Christine Garnett, et al.. (2013). The IQ‐CSRC Prospective Clinical Phase 1 Study: “Can Early QT Assessment Using Exposure Response Analysis Replace the Thorough QT Study?”. Annals of Noninvasive Electrocardiology. 19(1). 70–81. 81 indexed citations
17.
Dota, Corina, Leif Carlsson, Lars Frison, et al.. (2012). Assessment of Ventricular Repolarization Variability with the DeltaT50 Method Improves Identification of Patients with Congenital Long QT Syndromes. Annals of Noninvasive Electrocardiology. 18(3). 240–250. 3 indexed citations
18.
Dota, Corina, Lena Carlsson, Lars Frison, et al.. (2011). DeltaT50—a new method to assess temporal ventricular repolarization variability. Journal of Electrocardiology. 44(4). 477.e1–477.e9. 5 indexed citations
19.
Dota, Corina, et al.. (2003). Inter‐ and Intraday Variability in Major Electrocardiogram Intervals and Amplitudes in Healthy Men and Women. Pacing and Clinical Electrophysiology. 26(1p2). 361–366. 12 indexed citations
20.
Dota, Corina, et al.. (2002). Computer‐Based Analysis of Dynamic QT Changes: Toward High Precision and Individual Rate Correction. Annals of Noninvasive Electrocardiology. 7(4). 289–301. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026